|
|
| (55 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| − | {{tp|p=32251543|t=2020. The COVID-19 (Coronavirus) pandemic: reflections on the roles of librarians and information professionals |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | | | |
| Zeile 8: |
Zeile 6: |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| | + | *'''[[Clinical guidelines and advice]]''' |
| | | | |
| | | | |
| − |
| |
| − | *'''[[Clinical guidelines and advice]]'''
| |
| | | | |
| | *'''[[Respiration mgmt]]''' | | *'''[[Respiration mgmt]]''' |
| − |
| |
| | | | |
| | *'''[[Diagnosis (Laboratory)]]''' | | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{ttp|p=32357381|t=2020. Respiratory sampling for severe acute respiratory syndrome coronavirus 2: An Overview |pdf=|usr=}}
| |
| − | {{tp|p=32329102|t=2020. Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | {{ttp|p=32357377|t=2020. Performing the nasopharyngeal and oropharyngeal swab for 2019-novel coronavirus (SARS-CoV-2) safely: How to dress, undress, and technical notes |pdf=|usr=}}
| |
| − | {{ttp|p=32352180|t=2020. COVID-19: Nasal and oropharyngeal swab |pdf=|usr=}}
| |
| − | {{tp|p=32329138|t=2020. Who should perform the rhinopharyngeal swab in COVID-19 positive patients?|pdf=|usr=}}
| |
| − | {{tp|p=32356761|t=2020. Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Diagnosis (Lung CT, Sonography)]]''' | | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| − | {{ttp|p=32305937|t=2020. Review of Artificial Intelligence Techniques in Imaging Data Acquisition, Segmentation and Diagnosis for COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Diagnosis (other modalities)]]''' | | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32169673|t=2020. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{ttp|p=32374903|t=2020. SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate |pdf=|usr=}}
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| | | | |
| Zeile 51: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| Zeile 57: |
Zeile 39: |
| | | | |
| | | | |
| − | ----
| |
| | *'''[[Pathobiology]]''' | | *'''[[Pathobiology]]''' |
| − | {{tp|p=32364407|t=2020. COVID-19 Lung Injury Is Different From High Altitude Pulmonary Edema (Re: High Alt Med Biol Epub ahead of print ; DOI: 10 1089/ham 2020 0055) |pdf=|usr=}}
| + | |
| − | {{tp|p=32281877|t=2020. COVID-19 Lung Injury is Not High Altitude Pulmonary Edema |pdf=|usr=}}
| + | |
| − | {{tp|p=32374419|t=2020. Pulmonary Pathology of Early Phase COVID-19 Pneumonia in a Patient with a Benign Lung Lesion |pdf=|usr=}}
| + | |
| − | {{ttp|p=32364264|t=2020. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Disease Models]]''' | | *'''[[Disease Models]]''' |
| | + | |
| | | | |
| | *'''[[Similar diseases and pathomechanisms]]''' | | *'''[[Similar diseases and pathomechanisms]]''' |
| − | {{tp|p=32319148|t=2020. COVID-19: searching for clues among other respiratory viruses |pdf=|usr=}}
| |
| | | | |
| − |
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| Zeile 78: |
Zeile 53: |
| | | | |
| | *'''[[Systemic disease, any manifestations]]''' | | *'''[[Systemic disease, any manifestations]]''' |
| | + | |
| | *'''[[Co-Infection]]''' | | *'''[[Co-Infection]]''' |
| − | {{ttp|p=32265235|t=2020. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case |pdf=|usr=}}
| |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| | *'''[[Pulmonary embolism, coagulation]]''' | | *'''[[Pulmonary embolism, coagulation]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Hematology]]''' | | *'''[[Hematology]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Heart]]''' | | *'''[[Heart]]''' |
| − | {{tp|p=32354798|t=2020. Acute myocardial injury is common in patients with covid-19 and impairs their prognosis |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Neurology, ophthalmology, orl]]''' | | *'''[[Neurology, ophthalmology, orl]]''' |
| − | {{tp|p=32342566|t=2020. Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases |pdf=|usr=}}
| + | |
| − | {{tp|p=32317428|t=2020. What ophthalmologists should know about conjunctivitis in the COVID-19 pandemic?|pdf=|usr=}}
| + | |
| − | {{tp|p=32366336|t=2020. Olfactory and gustatory dysfunction caused by SARS-CoV-2: comparison with cases of infection with influenza and other viruses |pdf=|usr=}}
| + | |
| − | {{tp|p=32342636|t=2020. Potential pathogenesis of ageusia and anosmia in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32329222|t=2020. Self-reported olfactory loss associates with outpatient clinical course in Covid-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32301284|t=2020. Smell dysfunction: a biomarker for COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Dermatology]]''' | | *'''[[Dermatology]]''' |
| − | {{tp|p=32380219|t=ä. Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France |pdf=|usr=}}
| + | |
| − | {{tp|p=32380215|t=ä. Reply to ?Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients?: discussing specificity |pdf=|usr=}}
| + | |
| − | {{tp|p=32358979|t=2020. Diffuse cutaneous manifestation in a new mother with COVID-19 (SARS-Cov-2) |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Gastroenterology, hepatology]]''' | | *'''[[Gastroenterology, hepatology]]''' |
| − | {{tp|p=32241899|t=2020. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32139552|t=2020. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32327526|t=2020. Severe liver failure during SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32279064|t=2020. Coronavirus Disease (COVID-19) and the Gastrointestinal System in Children |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Kidney, urology]]''' |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| − | *'''[[Kidney, urology]]'''
| |
| | | | |
| | | | |
| − | *'''[[Risk and special populations]]''' | + | *'''[[Case reports]]''' |
| − | {{tp|p=32376422|t=ä. Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern |pdf=|usr=}}
| + | |
| − | {{tp|p=32380214|t=ä. Clinical considerations for managing dermatology patients on systemic immunosuppressive and/or biologic therapy during COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32245909|t=2020. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis |pdf=|usr=}}
| + | |
| − | {{tp|p=32312788|t=2020. Covid-19 infection in Crohn s disease under treatment with adalimumab |pdf=|usr=}}
| + | |
| − | {{tp|p=32307955|t=2020. COVID-19, THE KIDNEY AND HYPERTENSION |pdf=|usr=}}
| + | |
| − | {{tp|p=32220017|t=2020. Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient |pdf=|usr=}}
| + | |
| − | {{tp|p=32340044|t=2020. The ACE-2 in COVID-19: Foe or Friend?|pdf=|usr=}}
| + | |
| − | {{tp|p=32208987|t=2020. Renin-angiotensin system (RAS) blockers and the COVID-19 pandemic: at present there is no evidence to abandon RAS blockers |pdf=|usr=}}
| + | |
| − | {{tp|p=32367746|t=2020. ACE2, COVID-19, and ACE Inhibitor and ARB Use during the Pandemic: The Pediatric Perspective |pdf=|usr=}}
| + | |
| − | {{tp|p=32348166|t=2020. Effects Of ARBs And ACEIs On Virus Infection, Inflammatory Status And Clinical Outcomes In COVID-19 Patients With Hypertension: A Single Center Retrospective Study |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | | | |
| − | *'''[[The morbid survivor]]'''
| |
| − | *'''[[Case reports]]'''
| |
| | | | |
| | | | |
| Zeile 144: |
Zeile 101: |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − |
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| Zeile 152: |
Zeile 106: |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=32298218|t=2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19 |pdf=|usr=}}
| |
| − | {{tp|p=32317431|t=2020. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future |pdf=|usr=}}
| |
| − | {{tp|p=32370727|t=2020. SARS-CoV-2 & Covid-19: Key-Roles of the Renin-Angiotensin System / Vitamin D Impacting Drug and Vaccine Developments |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| | | | |
| − | ----
| + | *'''[[Biophysics of aerosols]]''' |
| | + | |
| | | | |
| | | | |
| − | *'''[[Other routes of infection]]'''
| |
| − | *'''[[Biophysics of aerosols]]'''
| |
| | | | |
| | *'''[[Passive protective equipment]]''' | | *'''[[Passive protective equipment]]''' |
| − | {{tp|p=32246972|t=2020. Ultraviolet germicidal irradiation: Possible method for respirator disinfection to facilitate reuse during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32319881|t=2020. May hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection?|pdf=|usr=}}
| + | |
| − | {{tp|p=32299521|t=2020. Environmental cleaning is effective for the eradication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in contaminated hospital rooms: A patient from the Diamond Princess cruise ship |pdf=|usr=}}
| + | |
| − | {{tp|p=32337516|t=2020. Use of free CAD design software for 3D printing individualized face masks based on face scans |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32358855|t=2020. Tracheostomy during COVID-19 pandemic-Novel approach |pdf=|usr=}}
| + | |
| − | {{tp|p=32298034|t=2020. How to avoid nosocomial spread during tracheostomy for COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32270574|t=2020. Improving staff safety during tracheostomy in COVID-19 patients |pdf=|usr=}}
| + | |
| − | {{tp|p=32348600|t=2020. Bronchoscopy, laryngoscopy, and esophagoscopy during the COVID-19 pandemic |pdf=|usr=}}
| + | |
| − | {{tp|p=32348582|t=2020. Clinical trials during COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32365278|t=2020. Management of COVID-19 in hemodialysis patients: The Genoa experience |pdf=|usr=}}
| + | |
| − | {{tp|p=32321619|t=2020. How we mitigate and contain COVID-19 outbreak in hemodialysis center (HD): lessons and experiences |pdf=|usr=}}
| + | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − |
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| | + | |
| | + | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Occupational medicine, workplace security and status hygienicus]]''' | | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | + | |
| | + | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| | | | |
| Zeile 197: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | + | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32325535|t=2020. Covid-19 in Fluchtlingsunterkunften: OGD jetzt weiter starken |pdf=|usr=}}
| + | |
| − | {{tp|p=32338071|t=2020. Racial Capitalism: A Fundamental Cause of Novel Coronavirus (COVID-19) Pandemic Inequities in the United States |pdf=|usr=}}
| + | |
| − | {{ttp|p=32378252|t=2020. A phased approach to unlocking during the COVID-19 pandemic-Lessons from trend analysis |pdf=|usr=}}
| + | |
| − | {{tp|p=32301199|t=2020. Estimation of basic reproduction number for COVID-19 and the reasons for its differences |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | *'''[[Remission, recurrence and persistence]]''' | | *'''[[Remission, recurrence and persistence]]''' |
| | + | |
| | + | |
| | | | |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | *'''[[Failure of politics and public health guidance]]''' | | *'''[[Failure of politics and public health guidance]]''' |
| − | {{tp|p=32352911|t=2020. COVID-19 reveals weak health systems by design: Why we must re-make global health in this historic moment |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| | | | |
| − | *'''[[Lost people]]'''
| |
| − | {{tp|p=32317499|t=2020. A tribute to frontline corona warriors--Doctors who sacrificed their life while saving patients during the ongoing COVID-19 pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Lost people]]''' |
| | | | |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| | + | *'''[[misc.]]''' |
| | | | |
| | | | |
| − | *'''[[misc.]]'''
| |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| − | {{tp|p=32339250|t=2020. A potential ex vivo infection model of human induced pluripotent stem cell-3D organoids beyond coronavirus disease 2019 |pdf=|usr=}} | + | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | | | |
| | | | |
| | *'''[[PrePrint scene]]''' | | *'''[[PrePrint scene]]''' |
| | + | |
| | + | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| | + | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | *'''[[on-topic personal thoughts]]''' | | *'''[[on-topic personal thoughts]]''' |
| − | {{tp|p=32338071|t=2020. Racial Capitalism: A Fundamental Cause of Novel Coronavirus (COVID-19) Pandemic Inequities in the United States |pdf=|usr=}}
| |
